Amgen Inc. disclosed on May 22nd that it has received a subpoena from the New York state attorney general seeking documents related to its promotions, sales and marketing activities for its biologic drugs.

Amgen received the subpoena May 10, according to a Securities and Exchange Commission filing. "Amgen intends to fully cooperate in responding to the subpoena," the company said in the filing.

In addition to focusing on the company's promotions, sales and marketing activities, the subpoena also sought documents related to medical education, clinical studies, pricing and contracting, license and distribution agreements and corporate communications.

Amgen said the U.S. Senate Finance Committee also sent a letter to the company on May 16 requesting a briefing to discuss the issues and concerns reported in the media related to the marketing and safety of biologic anemia drugs.

An advisory panel of the U.S. Food and Drug Administration earlier this month recommended that new restrictions be placed on prescribing Amgen biologics Aranesp and Epogen.

Amgen also said it was served May 14 with a shareholder demand that the company's board of directors create a special litigation committee to investigate potential breaches in fiduciary duties by current and/or former officers and directors of the company.

In addition, a class-action shareholder lawsuit was filed against Amgen and individual defendants in U.S. District Court on May 11, according to the SEC filing.